| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.01 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.31 | 0.01 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |